Showing 1451-1460 of 5771 results for "".
- Haag-Streit Announces Winners of its Slit Lamp Imaging Competition 2023https://modernod.com/news/haag-streit-announces-winners-of-its-slit-lamp-imaging-competition-2023/2481881/Attracting over 350 images from around the world, Haag-Streit Announced its top three winners of its Slit Lamp Imaging Competition 2023. The winners were judged on on image quality, technical execution, and disease interest. • First place: Pia Emilia Lohr
- Bausch + Lomb to Present New Scientific Data and Analyses at American Academy of Optometry Annual Meetinghttps://modernod.com/news/bausch-lomb-to-present-new-scientific-data-and-analyses-at-american-academy-of-optometry-annual-meeting/2481865/Bausch + Lomb announced one podium presentation and four poster presentations during the American Academy of Optometry (AAOpt)
- Sight Sciences Announces New MIGS Data Demonstrating TCOR Using OMNI Surgical System Lowers IOP and Medication Use at 2 Yearshttps://modernod.com/news/sight-sciences-announces-new-migs-data-demonstrating-tcor-using-omni-surgical-system-lowers-iop-and-iop-reducing-medications-at-2-years/2481863/Sight Sciences announced the results of the large scale, comparative real-world clinical outcomes study of patients treated by three leading minimally invasive glaucoma surgery (MIGS) technologies, which were recently presented at the 41st Congress of the European Society of Cataract an
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT
- Oculus Announces Parnership with Luvo to Offer New IPL and RF Devices for the US Ophthalmic Markethttps://modernod.com/news/oculus-announces-parnership-with-luvo-to-offer-new-ipl-and-rf-devices-for-the-us-ophthalmic-market/2481853/Oculus has announced a strategic partnership with Luvo to bring new specialty care devices to the US optometry and ophthalmology market. As part of the deal, Oculus is launching the Luvo Lucent and Darwin with Intense Pulse Light and Radio Frequency therapy, which are designed to e
- Thea Pharma Announces the US Launch of Glaucoma Drug Iyuzehhttps://modernod.com/news/thea-pharma-announces-the-us-launch-of-glaucoma-drug-iyuzeh/2481850/Thea Pharma announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh, which received FDA approval in December 2022, is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (
- PPG, Flō-Optics Announce Supplier Agreement for Digitally Applied Optical Coatingshttps://modernod.com/news/ppg-flo-optics-announce-supplier-agreement-for-digitally-applied-optical-coatings/2481849/PPG announced an exclusive supplier agreement with Flō-Optics, a developer of digital manufacturing technology for the ophthalmic industry, for the application of PPG HI-GARD scratch-resistant coatings using Flō’s proprietary digital printing technology. Financial terms of th
- OcuCell Announces Funding from the Georgia Eye Bankhttps://modernod.com/news/ocucell-announces-funding-from-the-georgia-eye-bank/2481845/OcuCell, a provider of ocular cell therapy, announce funding from the Georgia Eye Bank. Founded in 1961, Georgia Eye Bank has provided over 60,000 corneas for transplant and is dedicated to improving vision and lives through transplantation of ocular tissue and cells. Fin
- Zeiss Sets Date for Annual Zeiss Innovation Weekhttps://modernod.com/news/zeiss-sets-date-for-annual-zeiss-innovation-week/2481840/Zeiss announced its its annual
- Ocugen Announces Positive Update from the Phase 1/2 Trial of OCU400, a Gene Therapy Candidate for the Treatment of RP and LCAhttps://modernod.com/news/ocugen-announces-positive-update-from-the-phase-12-trial-of-ocu400-a-gene-therapy-candidate-for-the-treatment-of-rp-and-lca/2481836/Ocugen announced a clinical study update for retinitis pigmentosa (RP) participants treated in the phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations, and Leber congenital amaurosis (LCA) with mutation(s) in the CE